OST-HER2
Osteosarcoma (HER2+)
Key Facts
About OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileAbout OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileAbout OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileAbout OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileAbout OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileAbout OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profileAbout OS Therapies
OS Therapies is dedicated to revolutionizing cancer treatment by developing innovative immunotherapies for aggressive, underserved cancers. Its core technology platform includes OST-HER2, a novel immunotherapy that targets HER2 to induce a broad anti-tumor T-cell response, and the OST-tADC platform, a next-generation tunable antibody-drug conjugate system. The company is strategically focused on first addressing the urgent unmet need in osteosarcoma before expanding into other HER2-positive cancers such as breast, colorectal, and pancreatic cancers.
View full company profile